Influenza Clinical Trial
Official title:
Monitoring Seasonal and Pandemic Vaccine Safety and Effectiveness in Healthcare Providers:A Prospective Cohort Study
The overall objective of this study is to provide ongoing assessment of the safety and effectiveness of seasonal and pandemic H1N1 vaccines in the prevention of ILI (influenza like illness), ILI-associated work absenteeism, and laboratory-confirmed influenza in a cohort of Canadian HCP (Health care providers). Given the uncertainties around the timing of the provision of seasonal influenza immunization to HCP for the 2009/10 influenza season, this study will focus on evaluation of safety and effectiveness of pandemic influenza immunization in Year 1 and evaluation of all recommended influenza vaccines in Years 2 and 3.
Participants in Year 1 (2009/10) will be recruited beginning Oct. 1 through the end of the
pandemic H1N1 influenza immunization campaign.
Participants will be followed from the day of vaccination until the end of the influenza
season approximately Oct-April for each season.
At the initial visit, participants will have 1 tube of blood (10cc) collected at the time of
enrolment to determine baseline antibody titres against pandemic H1N1 and the influenza
strains in the past and current year's seasonal influenza vaccines.
Participants will receive automated email reminders with links to follow-up web-based
questionnaires at weekly intervals following the completion of the baseline survey and until
the end of the influenza season.
If a participant reports a respiratory illness, they will receive a follow-up questionnaire
asking details of the illness including the occurrence of respiratory illness and associated
symptoms, contact with patients or household members that had respiratory illness,
respiratory symptom-related healthcare utilization, prescription or over-the-counter
products used for treatment of the respiratory illness, and number of days of work missed
due to respiratory illness or worked with symptomatic respiratory tract infection. An email
will be sent to each participant every Monday morning during the season reminding the
participant to complete their weekly diary and report and send in their nasal swab if they
have symptoms of an acute respiratory illness.
At the initial visit participants will be taught how to collect their nasal swab and will
practice doing their own swab in the presence of the study nurse/research associate.
Participants will be instructed to collect a nasal swab and return the swabs as soon as
possible after onset of ILI or respiratory illness (target < 48h after onset). Participants
will be asked to collect the swab if they develop symptoms compatible with a viral
respiratory tract infection (fever without an apparent source OR new symptoms with at least
2 of the following -cough, runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness,
malaise, myalgia, headache, fatigue OR one local symptom (runny/stuffy nose, sneezing,
sore/scratchy throat, hoarseness, cough) plus one systemic symptom (fever, malaise, myalgia,
headache, fatigue). If they prefer, a nasopharyngeal swab will be collected by a member of
the study team as soon as possible after the onset of symptoms.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |